Patents by Inventor Michael J. Rodriguez

Michael J. Rodriguez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SARS-COV2 MAIN PROTEASE INHIBITORS
    Publication number: 20240116946
    Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
    Type: Application
    Filed: October 3, 2023
    Publication date: April 11, 2024
    Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Scott E. Lazerwith, Jessica L. McKinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen
  • Pseudomycins useful against plant diseases
    Patent number: 7326689
    Abstract: Plants and crops subject to attack by fungal related diseases are protected or treated by the application of Pseudomycin compositions which were originally isolated from Pseudomonas syringae.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: February 5, 2008
    Assignees: Eli Lilly and Company, Montana State University
    Inventors: Gary Strobel, Michael J. Rodriguez
  • Soft-decision metric generation for higher order modulation
    Patent number: 7076000
    Abstract: A method (100) for simplifying soft-decision metric decisions in a M-ary modulation system includes determining (102) a single function for a soft-decision metric for each bit in a symbol by restricting the set of all possible Gray-coded constellation points to those closest to a boundary between a bit value of 0 and 1 for each bit in the input symbol and applying a predetermined function corresponding to the range of restricted constellation points to the entire possible range of symbols. A next step includes inputting (104) a symbol having real part, x, and an imaginary part, y. A next step includes (106) setting a soft-decision metric for each bit in the symbol using the predetermined function from the determining step (102).
    Type: Grant
    Filed: January 18, 2001
    Date of Patent: July 11, 2006
    Assignee: Motorola, Inc.
    Inventor: Michael J. Rodriguez
  • Method of making HIV protease inhibitors
    Patent number: 6693199
    Abstract: A method of making HIV protease inhibitors of general formula (1): These HIV compounds inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other antiviral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: November 21, 2002
    Date of Patent: February 17, 2004
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • Pseudomycins useful against plant diseases
    Publication number: 20040029797
    Abstract: Plants and crops subject to attack by fungal related diseases are protected or treated by the application of Pseudomycin compositions which were originally isolated from Pseudomonas syringae.
    Type: Application
    Filed: August 18, 2003
    Publication date: February 12, 2004
    Inventors: Gary A Strobel, Michael J. Rodriguez
  • Cyclic peptide antifungal agents
    Patent number: 6670324
    Abstract: The present invention relates to compounds of formula I: where R5 is a sugar moiety. The compounds are useful in inhibiting fungal and parasitic activity and infections.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: December 30, 2003
    Assignee: Eli Lilly and Company
    Inventors: James A. Jamison, Michael J. Rodriguez, Venkatraghavan Vasudevan
  • Method of making HIV protease inhibitors
    Publication number: 20030216569
    Abstract: A method of making HIV protease inhibitors of general formula (1): 1
    Type: Application
    Filed: November 21, 2002
    Publication date: November 20, 2003
    Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • HIV protease inhibitors
    Patent number: 6525215
    Abstract: Compounds useful as intermediates in the preparation of HIV protease inhibitors.
    Type: Grant
    Filed: June 21, 2001
    Date of Patent: February 25, 2003
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • Soft-decision metric generation for higher order modulation
    Publication number: 20020131515
    Abstract: A method (100) for simplifying soft-decision metric decisions in a M-ary modulation system includes determining (102) a single function for a soft-decision metric for each bit in a symbol by restricting the set of all possible Gray-coded constellation points to those closest to a boundary between a bit value of 0 and 1 for each bit in the input symbol and applying a predetermined function corresponding to the range of restricted constellation points to the entire possible range of symbols. A next step includes inputting (104) a symbol having real part, x, and an imaginary part, y. A next step includes (106) setting a soft-decision metric for each bit in the symbol using the predetermined function from the determining step (102).
    Type: Application
    Filed: January 18, 2001
    Publication date: September 19, 2002
    Applicant: Motorola, Inc.
    Inventor: Michael J. Rodriguez
  • HIV protease inhibitors
    Publication number: 20020077338
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other antiviral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Application
    Filed: June 21, 2001
    Publication date: June 20, 2002
    Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • HIV protease inhibitors
    Patent number: 6271235
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 7, 2001
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, Stephen W. Kaldor, Vincent J. Kalish, Siegfried Heinz Reich, Michael J. Rodriguez, Timothy A. Shepherd, John H. Tatlock, Louis Nickolaus Jungheim
  • Pharmaceutical compositions containing HIV protease inhibitors and methods of their use
    Patent number: 6162812
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: April 1, 1999
    Date of Patent: December 19, 2000
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • Glycopeptide antibiotic derivatives
    Patent number: 5977062
    Abstract: The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity against a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also provided.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: November 2, 1999
    Assignee: Eli Lilly and Company
    Inventors: Robin D. G. Cooper, Bret E. Huff, Thalia I. Nicas, John T. Quatroche, Michael J. Rodriguez, Nancy J. Snyder, Michael A. Staszak, Richard C. Thompson, Stephen C. Wilkie, Mark J. Zweifel
  • HIV protease inhibitors
    Patent number: 5952343
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 14, 1999
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • HIV protease inhibitors
    Patent number: 5859002
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 12, 1999
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Vincent J. Kalish, Siegfried H. Reich, John H. Tatlock, Michael J. Rodriguez
  • HIV protease inhibitors
    Patent number: 5852043
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 22, 1998
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Vincent J. Kalish, Siegfried Heinz Reich, John H. Tatlock, Michael J. Rodriguez
  • HIV protease inhibitors
    Patent number: 5846993
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 8, 1998
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, Stephen W. Kaldor, Vincent J. Kalish, Siegfried Heinz Reich, John H. Tatlock, Michael J. Rodriguez
  • Glycopeptide antibiotic derivatives
    Patent number: 5843889
    Abstract: The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity aginst a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also provided.
    Type: Grant
    Filed: March 12, 1997
    Date of Patent: December 1, 1998
    Assignee: Eli Lilly and Company
    Inventors: Robin D. G. Cooper, Bret E. Huff, Thalia I. Nicas, John T. Quatroche, Michael J. Rodriguez, Nancy J. Snyder, Michael A. Staszak, Richard C. Thompson, Stephen C. Wilkie, Mark J. Zweifel
  • Glycopeptide antibiotic derivatives
    Patent number: 5840684
    Abstract: The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity against a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also provided.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: November 24, 1998
    Assignee: Eli Lilly and Company
    Inventors: Robin D. G. Cooper, Bret E. Huff, Thalia I. Nicas, John T. Quatroche, Michael J. Rodriguez, Nancy J. Snyder, Michael A. Staszak, Richard C. Thompson, Stephen C. Wilkie, Mark J. Zweifel
  • HIV protease inhibitors
    Patent number: 5837710
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 17, 1998
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: William J. Hornback, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez